The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Analysis of the MOSAIC correlative cancer database integrating molecular cancer classification and tumor profiling to identify targeted treatment options for metastatic cancer.
 
Li Ma
No Relationships to Disclose
 
Kai Treuner
Employment - bioTheranostics
Stock and Other Ownership Interests - bioTheranostics
Patents, Royalties, Other Intellectual Property - Related to research conducted at Biotheranostics, Inc.
Travel, Accommodations, Expenses - bioTheranostics
 
Jenna Wong
Employment - Biotheranostics
Stock and Other Ownership Interests - Biotheranostics
Travel, Accommodations, Expenses - Biotheranostics
 
David R. Spigel
Leadership - ASCO (Inst)
Consulting or Advisory Role - Amgen (Inst); Aptitude Health (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Curio Science (Inst); Dracen (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Iksuda Therapeutics (Inst); Illumina (Inst); Intellisphere (Inst); Ipsen (Inst); Jazz Pharmaceuticals (Inst); Merck (Inst); Mirati Therapeutics (Inst); Molecular Templates (Inst); Nektar (Inst); Novartis (Inst); Novocure (Inst); Pfizer (Inst); PharmaMar (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Sanofi/Aventis (Inst); Seagen (Inst); Takeda (Inst); TRIPTYCH Health Partners (Inst); TRM Oncology (Inst)
Research Funding - Aeglea Biotherapeutics (Inst); Agios (Inst); Apollomics (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BIND Therapeutics (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); Clovis Oncology (Inst); cyteir (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Elevation Oncology (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); GRAIL (Inst); ImClone Systems (Inst); Immunogen (Inst); Ipsen (Inst); Janssen Oncology (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Molecular Partners (Inst); Nektar (Inst); Neon Therapeutics (Inst); Novartis (Inst); Novocure (Inst); Takeda (Inst); Tesaro (Inst); Transgene (Inst); University of Texas Southwestern Medical Center - Simmons Cancer Center (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genentech; Novartis
 
Catherine A. Schnabel
Employment - Biotheranostics
Leadership - Biotheranostics
Stock and Other Ownership Interests - Biotheranostics
Research Funding - Biotheranostics (Inst)
Patents, Royalties, Other Intellectual Property - Patents and IP related to being employed by Biotheranostics (Inst)
Travel, Accommodations, Expenses - Biotheranostics
 
F Anthony Greco
Honoraria - bioTheranostics
Consulting or Advisory Role - bioTheranostics
Speakers' Bureau - bioTheranostics